Donald Westerhausen, MD
Pulmonary Disease · Mishawaka, INNPI 1437491974
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 63.0% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2024 at $6,896 and has fallen 50.3% since, to $3,427 in 2025.
Across 210 payments — averaging $54.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- AstraZeneca$944
- GSK$739
- Grifols USA, LLC$331
- Sanofi$306
- Boehringer Ingelheim$214
- plus $2K from 25 others
What the payments were for
- Travel & lodging$1,49813%
- Food & beverage$4,35538%
- Education$5,50048%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $7,149 |
| AstraZeneca | 38 | $944 |
| GSK | 47 | $739 |
| Grifols USA, LLC | 15 | $331 |
| Sanofi | 12 | $306 |
| Boehringer Ingelheim | 9 | $214 |
| Amgen | 9 | $182 |
| Regeneron Healthcare Solutions, Inc. | 6 | $176 |
| Mylan Specialty L.p. | 7 | $162 |
| United Therapeutics Corporation | 7 | $161 |
| Genentech USA, Inc. | 6 | $133 |
| Verona Pharma, Inc. | 5 | $109 |
| Viatris Specialty LLC | 5 | $96 |
| Philips North America LLC | 4 | $92 |
| Merck | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $80 |
| Mallinckrodt Hospital Products Inc. | 3 | $54 |
| Actelion Pharmaceuticals US, Inc. | 3 | $46 |
| Inspire Medical Systems, Inc. | 1 | $44 |
| Siemens Medical Solutions USA, Inc. | 1 | $33 |
| Pulmonx Corporation | 2 | $30 |
| Baxter Healthcare | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Abbott | 1 | $24 |
| EMD Serono, Inc. | 1 | $21 |
| Inogen, Inc. | 1 | $20 |
| Insmed, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Circassia Inc. | 1 | $11 |
| Lundbeck LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,096
- AIRSUPRA$240
- NUCALA$125
- FASENRA$117
How this compares
$11,352 in reported general payments places this provider in the 80th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 17 | $147,693 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 158 | $145,768 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 62 | $49,068 |
| Spiriva RespimatTiotropium Bromide | 26 | $18,930 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $15,872 |
| Pirfenidone | 11 | $7,238 |
| AirsupraAlbuterol Sulfate/Budesonide | 14 | $6,529 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,070 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $4,775 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,333 |
| Varenicline Tartrate | 16 | $3,610 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 147 | $3,321 |
| Ventolin HfaAlbuterol Sulfate | 12 | $673 |
| Azelastine Hcl | 13 | $431 |
| Gabapentin | 13 | $162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta | $739 | $303,864202 claims |
| AstraZenecaBreztri Aerosphere, Airsupra, Symbicort | $944 | $60,37297 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $214 | $34,80347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Mishawaka
- Paul GuentertMishawaka$40K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.